It has been about a month since the last earnings report for Mirum Pharmaceuticals, Inc. (MIRM). Shares have lost about 1.9% in that time frame, outperforming the S&P 500. Will the recent negative ...

Shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM – Get Free Report) have earned a consensus rating of “Buy” from the eleven research firms that are presently covering the firm, MarketBeat reports.

Mirum Pharmaceuticals, Inc. shows strong growth with a 43% revenue jump and promising pipeline assets. Click here for my ...

Mirum Pharmaceuticals stock surged 25% and how LIVMARLI drives growth. Explore future prospects with Volixibat. Click here to ...

Mirum Pharmaceuticals’ MIRM lead product, Livmarli (maralixibat), an orally administered ileal bile acid transporter (“IBAT”) ...

Mirum Pharmaceuticals (MIRM) announced that its partner, Takeda (TAK), has received approval by the Japanese Ministry of Health, Labour, and ...

LIVMARLI is the first and only treatment available for cholestatic pruritus in patients with Alagille syndrome and ...

AlphaQuest LLC increased its position in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM – Free Report) by 969.6% in the 4th quarter ...

Morgan Stanley raised the firm’s price target on Mirum Pharmaceuticals (MIRM) to $65 from $63 and keeps an Overweight rating on the shares. Q4 was “uneventful” as pipeline progress remains ...

Revenue: US$336.9m (up 81% from FY 2023). Net loss: US$87.9m (loss narrowed by 46% from FY 2023). US$1.85 loss per share (improved from US$4.00 loss in FY 2023). Revenue was in line with analyst ...

Celsius and Alnylam rally but VNET falls. We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold ...